  |
The MedWatch March 2016 Safety Labeling Changes posting includes 35 products with safety labeling changes to the following sections: CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, and ADVERSE REACTIONS.
The "Summary Page" table provides a listing of product names and safety labeling sections revised:
http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm494834.htm
The following drugs had modifications to the CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS sections:
Adcetris (brentuximab vedotin) for Injection
Angiomax (bivalirudin) Lyophilized Powder for Injection
Droxia (hydroxyurea) and Hydrea (hydroxyurea) Capsules
Faslodex (fulvestrant) Solution for Injection
Furosemide Tablets, Injection and Lasix (furosemide) Tablets
Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) Fixed-dose Combination Tablet
Herceptin (trastuzumab) Intravenous Infusion
Implanon (etonogestrel) Implant
Invega (paliperidone) Extended-Release Tablets
Invega Sustenna (paliperidone palmitate) Extended-release Injectable Suspension
Invega Trinza (paliperidone palmitate) Extended-release Injectable Suspension
Invokamet (canagliflozin and metformin hydrochloride) Tablets
Invokana (canagliflozin) Tablets
Jakafi (ruxolitinib phosphate) Tablet
Juxtapid (lomitapide) Capsules
Klonopin (clonazepam) Tablets
Nexplanon (etonogestrel) Implants
Oxytrol for Women (oxybutynin) Transdermal System
PLASMA-LYTE 56 and 5% Dextrose Injection
Prezcobix (darunavir and cobicistat) Tablet
Renagel (sevelamer hydrochloride) Tablets
Renvela (sevelamer carbonate) Powder for Oral Suspension
Risperdal (risperidone) Tablets, Oral Solution and Risperdal M-TAB (risperidone) Orally Disintegrating Tablets
Risperdal Consta (risperidone) Long Acting Injection
Sustiva (efavirenz) Capsules and Tablets
Truvada (emtricitabine/tenofovir disoproxil fumarate) Tablets
Tudorza Pressair (aclidinium bromide inhalation powder)
Xgeva (denosumab, AMG 162; Human Monoclonal Antibody to RANK Ligand)
Zarxio (filgrastim-sndz)
You are encouraged to report all serious adverse events and product quality problems to FDA MedWatch at www.fda.gov/medwatch/report.htm
Update your subscriptions, modify your e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your email address to log in. If you have questions or problems with the subscription service, please visit subscriberhelp.govdelivery.com.
This service is provided to you at no charge by U.S. Food & Drug Administration (FDA).
| This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 1-888-INFO-FDA (1-888-463-6332) |  |
